Survodutide

What it is

Survodutide hits the glucagon and GLP-1 receptors. Retatrutide hits those two plus GIP. Tirzepatide hits GLP-1 plus GIP. Between them these three map out most of the incretin design space, and comparing them tells you what each arm actually contributes.

The glucagon arm is the one worth understanding. GLP-1 makes you eat less. Glucagon makes you burn more, by raising resting energy expenditure and pushing the liver to mobilise fat. Survodutide is the cleanest available test of that pairing without GIP muddying the picture.

What the evidence shows

SYNCHRONIZE-1, in adults with obesity and without diabetes, reported up to 16.6% mean weight loss. That sits between semaglutide's ~14.9% and tirzepatide's ~20.9%, which is roughly where you would expect a dual agonist without the GIP arm to land.

There is also encouraging phase 2 work in MASH, the liver disease, which is consistent with glucagon driving hepatic fat mobilisation. That mechanism keeps showing up across the glucagon-containing drugs and looks like a real class effect rather than a fluke.

The GIP arm, by subtraction

Put the three side by side and something useful falls out.

Tirzepatide has GIP and no glucagon, and produces the largest approved weight loss with unusually good tolerability. Survodutide has glucagon and no GIP, lands lower, and needs a notably slower titration to be tolerable. Retatrutide has both and produces the largest numbers of all.

The pattern suggests GIP is doing less for weight directly and more for making high exposures bearable in the first place. Survodutide's long escalation schedule is the visible cost of leaving it out.

Practical notes

• The titration is longer for a reason. Trials escalated over 16 to 24 weeks. Compressing that is the fastest way to make yourself miserable and quit.
• Watch resting heart rate. The glucagon arm raises it in a dose-dependent way, same as retatrutide.
• Nothing here is available legitimately. Survodutide has never been sold as a finished product, so anything offered under the name carries every sourcing problem described in safety and sourcing.

Side effects and warning signs

Commonly reported

• Nausea and vomiting, the dose-limiting problem in every trial so far
• Diarrhoea and constipation
• Modest heart rate increase, a glucagon-arm effect it shares with retatrutide
• Injection-site reactions

Stop and get medical help

• Vomiting severe enough that you cannot keep fluids down
• Severe abdominal pain radiating to the back
• Personal or family history of medullary thyroid carcinoma or MEN2

Sources

1. SYNCHRONIZE-1 phase 3 obesity results, Boehringer Ingelheimtrial
2. SYNCHRONIZE-2 baseline characteristics, Diabetes Obesity and Metabolism 2026trial

From the community

Discussion for this compound concentrates in r/GLP1 and r/Peptidesource.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.